Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

19 October 2026 · By · Wire by Fusion42

Published

19 October 2026

Topic

operational-macro

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 19 October 2026 · Fusion42 review

Haemonetics has received FDA approval for its PerQseal Elite Vascular Closure System, enabling its commercialisation and use in the US market.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

FDA approval opens the US market for vascular closure device startups with new commercial pathways emerging. You should engage US-based clinical partners and procurement early to capture new adoption waves.

◆ Coverage

2 sources · 19 Oct 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalvascular-closuremedtechus-market